HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

H Simon Schaaf Selected Research

Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis)

1/2024Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
11/2023Current Treatment of Drug-Resistant Tuberculosis in Children.
12/2022Hepatocellular Injury in Children Treated for Rifampicin-resistant Tuberculosis: Incidence, Etiology and Outcome.
11/2022Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis.
11/2022Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis.
1/2022Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial.
1/2022Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
1/2021Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis.
12/2020Adverse Events Associated With New Injectable-Free Multidrug-Resistant Tuberculosis Drug Regimens.
1/2019Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant Tuberculosis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


H Simon Schaaf Research Topics

Disease

41Tuberculosis (Tuberculoses)
01/2024 - 05/2006
29Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis)
01/2024 - 12/2007
8Infections
03/2022 - 05/2002
5Body Weight (Weight, Body)
12/2023 - 06/2009
5HIV Infections (HIV Infection)
01/2020 - 11/2007
5Hearing Loss (Hearing Impairment)
04/2013 - 01/2009
3Pulmonary Tuberculosis
01/2024 - 11/2006
3Malnutrition (Nutritional Deficiencies)
01/2023 - 11/2005
3Extensively Drug-Resistant Tuberculosis
09/2014 - 08/2009
2Immune Reconstitution Inflammatory Syndrome
04/2024 - 01/2008
2Coinfection
12/2022 - 03/2011
2Pain (Aches)
12/2018 - 11/2016
2Ototoxicity
11/2016 - 05/2012
1Hepatitis A (Hepatitis, Infectious)
12/2022
1Neoplasms (Cancer)
01/2021
1Abscess
01/2021
1Disease Progression
12/2018
1Bacterial Infections (Bacterial Infection)
01/2017
1Sensorineural Hearing Loss
11/2016
1Intracranial Hypertension
06/2016
1Hydrocephalus (Hydrocephaly)
10/2014
1Miliary Tuberculosis
01/2010
1Kwashiorkor
06/2009
1Deafness (Deaf Mutism)
01/2009

Drug/Important Bio-Agent (IBA)

18Rifampin (Rifampicin)FDA LinkGeneric
01/2024 - 05/2006
10Isoniazid (Ftivazide)FDA LinkGeneric
01/2023 - 05/2006
7Levofloxacin (Levaquin)FDA Link
01/2024 - 06/2016
5Tuberculin (PPD)IBA
01/2017 - 11/2005
4OPC-67683IBA
11/2022 - 09/2014
4Linezolid (Zyvox)FDA Link
01/2022 - 08/2009
4AminoglycosidesIBA
04/2013 - 01/2009
3PyrazinamideFDA LinkGeneric
01/2023 - 05/2014
3Aminosalicylic Acid (Rezipas)FDA Link
01/2023 - 01/2022
3TabletsIBA
01/2019 - 01/2018
3FluoroquinolonesIBA
01/2018 - 10/2014
2terizidoneIBA
12/2023 - 01/2022
2Cycloserine (Seromycin)FDA Link
12/2023 - 01/2022
2bedaquiline (R207910)IBA
11/2022 - 01/2022
2Moxifloxacin (Avelox)FDA Link
01/2022 - 02/2015
2AcidsIBA
01/2022 - 11/2006
2Amikacin (A.M.K)FDA LinkGeneric
12/2018 - 11/2016
2Biomarkers (Surrogate Marker)IBA
10/2016 - 10/2016
2Ofloxacin (Ofloxacine)FDA LinkGeneric
10/2015 - 12/2013
1GelatinIBA
12/2023
1Clofazimine (Lamprene)FDA Link
12/2023
1ProdrugsIBA
12/2023
1Hormones (Hormone)IBA
12/2022
1CytokinesIBA
12/2022
1Immunoglobulin M (IgM)IBA
12/2022
1Carbapenems (Carbapenem Antibiotics)IBA
01/2022
1insulin receptor-related receptor (IRR)IBA
01/2021
1BCG VaccineFDA Link
01/2021
1abacavir (Ziagen)FDA Link
01/2021
1Ethionamide (Trecator-SC)FDA Link
01/2020
1Lidocaine (Xylocaine)FDA LinkGeneric
12/2018
1Ritonavir (Norvir)FDA Link
01/2018
1LopinavirFDA Link
01/2018
1Streptomycin (Streptomycin Sulfate)FDA Link
01/2018
1lopinavir-ritonavir drug combination (Kaletra)FDA Link
01/2018
1Ethambutol (Myambutol)FDA LinkGeneric
01/2018
1Antitubercular AgentsIBA
01/2018
1RifamycinsIBA
04/2017
1ElectrolytesIBA
11/2016
1Capreomycin (Capastat)FDA Link
11/2016
1Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
11/2016
1Acetylcysteine (Siran)FDA LinkGeneric
11/2016
1KanamycinFDA Link
11/2016
1Indicators and Reagents (Reagents)IBA
10/2014
1Peptides (Polypeptides)IBA
04/2013
1GoldIBA
03/2013
1VaccinesIBA
12/2006

Therapy/Procedure

19Therapeutics
01/2020 - 11/2005
7Injections
01/2022 - 11/2012
6Drug Therapy (Chemotherapy)
11/2022 - 11/2006
4Chemoprevention
01/2010 - 05/2002
2Aftercare (After-Treatment)
01/2024 - 01/2022
2Highly Active Antiretroviral Therapy (HAART)
01/2010 - 01/2008
1Art Therapy
04/2024
1Intramuscular Injections
12/2018
1Duration of Therapy
06/2015
1Ambulatory Care (Outpatient Care)
03/2013